SCHEMBL15068209

SCHEMBL15068209

O=S(=O)(Nc1ccc(F)cc1)c1ccc(F)c(Br)c1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.61
CA2 P00918 1/20 0.61
ALDH1A1 P00352 5/20 0.53
MAPK1 P28482 2/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2C9 P11712 1/20 0.53
MAPT P10636 2/20 0.52
LMNA P02545 2/20 0.52
POLB P06746 2/20 0.51
PKM P14618 3/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
FFAR1 O14842 1/20 0.50
FFAR4 Q5NUL3 1/20 0.50
GPR27 Q9NS67 1/20 0.49
HSD17B3 P37058 1/20 0.49
HSD17B2 P37059 1/20 0.49
GFER P55789 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15068138 0.87 GPR27 (0.59) CA1CA2ALDH1A1MAPK1MAPT
SCHEMBL7501950 0.80 CA1 (0.81) CA1CA2ALDH1A1MAPK1CYP3A4
SCHEMBL3919353 0.80 CA1 (0.69) CA1CA2ALDH1A1MAPK1CYP3A4
Hydrochloric Acid SCHEMBL5797806 0.79 CA1 (0.79) CA1CA2ALDH1A1MAPK1CYP3A4
SCHEMBL7574073 0.78 CA1 (0.62) CA1CA2ALDH1A1MAPK1CYP3A4
SCHEMBL1489068 0.77 PGR (0.65) CA1CA2ALDH1A1MAPTPKM
SCHEMBL20779633 0.76 CA1 (0.50) CA1CA2ALDH1A1LMNAKMT2A
SCHEMBL3366221 0.76 CES1 (0.81) CA1CA2ALDH1A1MAPK1CYP3A4
SCHEMBL29561923 0.75 CA1 (0.63) CA1CA2ALDH1A1MAPK1CYP3A4
SCHEMBL19994857 0.74 GPR27 (0.59) CA1CA2ALDH1A1MAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230158039-A1 BROMODOMAIN INHIBITORS ABBVIE INC (US) 2023-05-25 US disclosed
US-20210236508-A1 BROMODOMAIN INHIBITORS ABBVIE INC (US) 2021-08-05 US disclosed
CN-106986872-B Bromodomain inhibitors 艾伯维公司 2020-04-21 CN disclosed
US-20180296566-A1 BROMODOMAIN INHIBITORS ABBVIE INC (US) 2018-10-18 US disclosed
EP-2797918-B1 BROMODOMAIN INHIBITORS ABBVIE INC (US) 2017-11-29 EP disclosed
US-20160143916-A1 BROMODOMAIN INHIBITORS ABBVIE INC (US) 2016-05-26 US disclosed
US-9296741-B2 Bromodomain inhibitors ABBVIE INC. (US) 2016-03-29 US disclosed
EP-2797918-A1 BROMODOMAIN INHIBITORS AbbVie Inc. (US) 2014-11-05 EP disclosed
US-20140162971-A1 BROMODOMAIN INHIBITORS ABBVIE INC. 2014-06-12 US disclosed
WO-2013097601-A1 BROMODOMAIN INHIBITORS ABBVIE INC. (US) 2013-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180296566-A1 BROMODOMAIN INHIBITORS BRD4, BRD1, BRD3 CA1 1571/4885CA2 2735/4885ALDH1A1 1794/4885
US-20140162971-A1 BROMODOMAIN INHIBITORS BRD4, BRD1, BRD3 CA1 1571/4885CA2 2735/4885ALDH1A1 1794/4885
US-20230158039-A1 BROMODOMAIN INHIBITORS BRD4, BRD1, BRD3 CA1 1571/4885CA2 2735/4885ALDH1A1 1794/4885
US-20160143916-A1 BROMODOMAIN INHIBITORS BRD4, BRD1, BRD3 CA1 1571/4885CA2 2735/4885ALDH1A1 1794/4885
US-20210236508-A1 BROMODOMAIN INHIBITORS BRD4, BRD1, BRD3 CA1 1571/4885CA2 2735/4885ALDH1A1 1794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.